CO2018001985A2 - Polipéptidos mrka, anticuerpos y usos de los mismos - Google Patents
Polipéptidos mrka, anticuerpos y usos de los mismosInfo
- Publication number
- CO2018001985A2 CO2018001985A2 CONC2018/0001985A CO2018001985A CO2018001985A2 CO 2018001985 A2 CO2018001985 A2 CO 2018001985A2 CO 2018001985 A CO2018001985 A CO 2018001985A CO 2018001985 A2 CO2018001985 A2 CO 2018001985A2
- Authority
- CO
- Colombia
- Prior art keywords
- mrka
- klebsiella
- antibodies
- fragments
- subject
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 4
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 241000588748 Klebsiella Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 206010061259 Klebsiella infection Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000625 opsonophagocytic effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208975P | 2015-08-24 | 2015-08-24 | |
| US201562238828P | 2015-10-08 | 2015-10-08 | |
| PCT/US2016/048221 WO2017035154A1 (en) | 2015-08-24 | 2016-08-23 | Mrka polypeptides, antibodies, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018001985A2 true CO2018001985A2 (es) | 2018-11-22 |
Family
ID=58100831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0001985A CO2018001985A2 (es) | 2015-08-24 | 2018-02-23 | Polipéptidos mrka, anticuerpos y usos de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170073397A1 (enExample) |
| EP (1) | EP3341004A4 (enExample) |
| JP (1) | JP2018527924A (enExample) |
| KR (1) | KR20180042300A (enExample) |
| CN (1) | CN107921086A (enExample) |
| AU (1) | AU2016313653A1 (enExample) |
| BR (1) | BR112018003252A2 (enExample) |
| CA (1) | CA2995387A1 (enExample) |
| CL (1) | CL2018000357A1 (enExample) |
| CO (1) | CO2018001985A2 (enExample) |
| HK (1) | HK1252350A1 (enExample) |
| IL (1) | IL257434A (enExample) |
| MX (1) | MX2018001964A (enExample) |
| RU (1) | RU2018107056A (enExample) |
| TW (1) | TW201718626A (enExample) |
| WO (1) | WO2017035154A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900027XA (en) * | 2016-08-05 | 2019-02-27 | Medimmune Llc | Anti-o2 antibodies and uses thereof |
| WO2018075375A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
| JP2020525540A (ja) | 2017-06-23 | 2020-08-27 | ノソコミアル ヴァクスィーン コーポレイション | 免疫原性組成物 |
| CN115838430A (zh) * | 2022-07-08 | 2023-03-24 | 中国人民解放军陆军军医大学 | 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用 |
| CN116813725B (zh) * | 2023-07-06 | 2025-11-04 | 深圳康泰生物制品股份有限公司 | 肺炎克雷伯菌的FimA的抗原表位肽及其应用 |
| CN119798389A (zh) * | 2024-12-12 | 2025-04-11 | 中国人民解放军军事科学院军事医学研究院 | 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| WO2001010386A2 (en) * | 1999-08-11 | 2001-02-15 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| US7041465B1 (en) * | 1999-08-11 | 2006-05-09 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| WO2005034733A2 (en) * | 2003-10-08 | 2005-04-21 | North Shore-Long Island Jewish Research Institute | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| EA018030B1 (ru) * | 2006-06-06 | 2013-05-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| EP2152731A2 (en) * | 2007-05-02 | 2010-02-17 | Intercell AG | Klebsiella antigens |
| GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
| WO2011100700A2 (en) * | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| WO2012058334A1 (en) * | 2010-10-26 | 2012-05-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Morphology & protein specific reagents as diagnostics for neurodegenerative diseases |
| SMT202000542T1 (it) * | 2011-11-07 | 2020-11-10 | Medimmune Ltd | Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas |
-
2016
- 2016-08-23 MX MX2018001964A patent/MX2018001964A/es unknown
- 2016-08-23 HK HK18111635.8A patent/HK1252350A1/zh unknown
- 2016-08-23 TW TW105126946A patent/TW201718626A/zh unknown
- 2016-08-23 US US15/244,960 patent/US20170073397A1/en not_active Abandoned
- 2016-08-23 AU AU2016313653A patent/AU2016313653A1/en not_active Abandoned
- 2016-08-23 KR KR1020187007376A patent/KR20180042300A/ko not_active Withdrawn
- 2016-08-23 WO PCT/US2016/048221 patent/WO2017035154A1/en not_active Ceased
- 2016-08-23 BR BR112018003252A patent/BR112018003252A2/pt not_active Application Discontinuation
- 2016-08-23 RU RU2018107056A patent/RU2018107056A/ru not_active Application Discontinuation
- 2016-08-23 CA CA2995387A patent/CA2995387A1/en not_active Abandoned
- 2016-08-23 CN CN201680047771.3A patent/CN107921086A/zh active Pending
- 2016-08-23 EP EP16839995.4A patent/EP3341004A4/en not_active Withdrawn
- 2016-08-23 JP JP2018509904A patent/JP2018527924A/ja active Pending
-
2018
- 2018-02-08 CL CL2018000357A patent/CL2018000357A1/es unknown
- 2018-02-08 IL IL257434A patent/IL257434A/en unknown
- 2018-02-23 CO CONC2018/0001985A patent/CO2018001985A2/es unknown
- 2018-03-29 US US15/940,344 patent/US20190062411A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1252350A1 (zh) | 2019-05-24 |
| CL2018000357A1 (es) | 2018-07-20 |
| JP2018527924A (ja) | 2018-09-27 |
| TW201718626A (zh) | 2017-06-01 |
| US20170073397A1 (en) | 2017-03-16 |
| AU2016313653A1 (en) | 2018-04-12 |
| IL257434A (en) | 2018-04-30 |
| RU2018107056A (ru) | 2019-09-26 |
| CN107921086A (zh) | 2018-04-17 |
| MX2018001964A (es) | 2018-06-19 |
| US20190062411A1 (en) | 2019-02-28 |
| EP3341004A1 (en) | 2018-07-04 |
| EP3341004A4 (en) | 2019-05-15 |
| WO2017035154A1 (en) | 2017-03-02 |
| BR112018003252A2 (pt) | 2018-09-25 |
| KR20180042300A (ko) | 2018-04-25 |
| CA2995387A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018001985A2 (es) | Polipéptidos mrka, anticuerpos y usos de los mismos | |
| CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
| BR112018014615A2 (pt) | composições de anticorpo para ror1 e métodos relacionados | |
| BR112018012352A2 (pt) | anticorpos anti-lag3 e fragmentos de ligação ao antígeno | |
| CO2018003436A2 (es) | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso | |
| CU20170169A7 (es) | Anticuerpos de factor xi | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| BR112017025191A2 (pt) | anticorpos contra ox40 e uso dos mesmos | |
| BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
| EA201591611A1 (ru) | Конъюгаты антитело-лекарственное средство | |
| MX2016002166A (es) | Anticuerpos. | |
| AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| MX2018009506A (es) | Vacunas contra el cáncer y métodos de tratamiento que las utilizan. | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
| MX390418B (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso. | |
| BR112017025533A2 (pt) | método para tratar câncer em um paciente humano | |
| AR108975A1 (es) | Anticuerpos con baja inmunogenicidad y sus usos | |
| MX2017004196A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| BR112017013420A2 (pt) | anticorpo adam17 humanizado |